Alfa Cytology's OncoBact™ platform employs engineered bacterial vectors to achieve tumor microenvironment-specific targeting. By exploiting hypoxia/acidosis-responsive promoters, our platform enables oncolytic bacteria to selectively replicate in solid tumors while sparing healthy tissues. This breakthrough technology ensures precise therapeutic payload delivery for enhanced anti-cancer efficacy.
Learn More
Select for Alfa Cytology's one-stop oncolytic bacterial therapy development platform and embark on a hassle-free and efficient R&D journey. We offer a full-spectrum service, from bacterial strain screening and genetic engineering to preclinical trial design and execution. By integrating industry resources and assembling top-notch professional teams, we're dedicated to propelling your oncolytic bacterial therapy projects forward.
Learn More
At Alfa Cytology's oncolytic bacteria-based combination therapy platform, we break the limitations of single-modality treatments. We artfully combine oncolytic bacterial therapy with other advanced treatment modalities, such as immunotherapy and radiotherapy. Through synergistic effects, we enhance treatment efficacy, offering innovative and comprehensive solutions to tackle complex cancer challenges.
Learn More
